Jeffrey M. Rosen

This study identifies an early neutrophil interferon program that predicts resistance to anti-PD1 therapy and limits durable anti-tumor immunity.

This paper shows that combining MERTK inhibition with cyclophosphamide enhances anti-tumor immunity in basal-like TNBC by reprogramming macrophages and promoting CD4 T cell responses.

The paper shows that combining anti-CSF-1R therapy with chemotherapy and anti-PD-1 improves immune response in metastatic TNBC by reducing macrophages and increasing T/B cell infiltration.

CBP/P300 BRD inhibition reduces neutrophil accumulation and enhances antitumor immunity in neutrophil-enriched TNBC, improving responses to standard therapies.

Zotatifin targets EIF4A to suppress TNBC by inhibiting Sox4, inducing interferon response, and reprogramming the tumor immune microenvironment, synergizing with chemotherapy.